Skip to main content
OpenTrials
Completed

NCT Number: NCT01576016

Safety and Efficacy of the Accent Magnetic Resonance Imaging™ (MRI) Pacemaker and Tendril MRI™ Lead

The MRI Study is a prospective, multi-center, clinical study designed to evaluate the safety and efficacy of the Accent MRI™ System in a patient population indicated for implant of a pacemaker within and outside of the MRI environment.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

St. Andrews Hospital, Adelaide, South Australia, Australia

Loading trial locations.

About this study

The MRI Study is a prospective, multi-center, clinical study designed to evaluate the safety and efficacy of the Accent MRI System in a patient population indicated for implant of a pacemaker within and outside of the MRI environment. The study consisted of two phases, a Lead Safety Phase which evaluated the safety of the Tendril MRI lead, and an MRI Phase which evaluated the safety and efficacy of the Accent MRI pacemaker system in an MRI environment.

The safety and efficacy of the Accent MRI pacemaker and Tendril MRI lead will be evaluated as described below:

Lead Safety Safety of the Tendril MRI™ lead will be evaluated in terms of freedom from right atrial (RA) and right ventricle (RV) lead-related complications at implant to 2 months (acute timeframe), and at the 2 through the 12 month visit (chronic timeframe).

MRI Safety The safety of the Accent MRI™ system will be evaluated in terms of freedom from MRI scan related complications in the month following the MRI scan.

Lead Efficacy Efficacy of the Tendril MRI™ lead will be evaluated in terms of the change in atrial and ventricular capture and sensing thresholds before and after the MRI scan.

MRI Efficacy Efficacy of the Tendril MR lead will be evaluated in terms of the change in bipolar atrial and ventricular capture and sensing thresholds before and after the MRI scan.

Secondary Endpoints Safety Safety of the Accent MRI™ system will be evaluated in terms of freedom from system-related complications through the 12 month visit.

Efficacy Efficacy of the Tendril MRI™ lead will be evaluated in terms of the atrial and ventricular capture thresholds at the MRI Visit.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Eligible patients will meet all of the following:

  • Have an approved indication per American College of Cardiology (ACC)/American Heart Association (AHA)/Heart Rhythm Society (HRS) guidelines for implantation of a pacemaker
  • Will receive a new pacemaker and lead
  • Be willing to undergo an elective MRI scan without sedation
  • Be able to provide informed consent for study participation (legal guardian is NOT acceptable)
  • Be willing and able to comply with the prescribed follow-up tests and schedule of evaluations
  • Is not contraindicated for an MRI scan (per the pre-MRI safety screening form)

Exclusion criteria

Patients will be excluded if they meet any of the following:

  • Are medically indicated for an MRI scan at the time of enrollment
  • Have an existing pacemaker or implantable cardioverter defibrillator (ICD). A new pacemaker and lead is required for enrollment
  • Have an existing active/inactive implanted medical device, e.g., neurostimulator, infusion pump, etc.
  • Have a non-MRI compatible device or material implanted (e.g., intracranial aneurysm clip, non-MRI compatible devices or material, metals or alloys, etc.)
  • Have a lead extender or adaptor
  • Be unable to fit in MRI bore; will come into contact with the magnet façade inside the MRI bore.
  • Have a prosthetic tricuspid heart valve
  • Are currently participating in a clinical investigation that includes an active treatment arm
  • Are allergic to dexamethasone sodium phosphate (DSP)
  • Are pregnant or planning to become pregnant during the duration of the study
  • Have a life expectancy of less than 12 months due to any condition
  • Patients with exclusion criteria required by local law (e.g., age)
  • Are unable to comply with the follow up schedule

Treatment and study plan

Accent MRI system (lead safety)

Device

Patients implanted with an Accent MRI system

Other names: Accent MRI pacemaker, Tendril MRI lead

Accent MRI system (with MRI scan)

Device

Patients implanted with an Accent MRI system will receive an MRI scan

Other names: Accent MRI pacemaker, Tendril MRI lead

Primary outcomes

  1. Freedom From Right Atrial (RA) Lead-related Complications in the Acute Period

    Time frame: Implant through 2 months

    Percentage of patients who do not have RA lead-related complications from implant through the 2 month study visit

  2. Freedom From Right Ventricular (RV) Lead-related Complications in the Acute Time Period

    Time frame: Implant through 2 months

    Percentage of patients who do not have RV lead-related complications from implant through the 2 month study visit

  3. Freedom From RA Related Complications in the Chronic Period

    Time frame: 2 months through 12 months

    Percentage of patients who do not have RA lead-related complications from the 2 month through the 12 month study visit

  4. Freedom From Right Ventricular Lead Related Complications in the Chronic Period

    Time frame: 2 months through 12 months

    Percentage of patients who do not have RV lead-related complications from the 2 month through the 12 month study visit

  5. Freedom From MRI Scan-related Complications

    Time frame: MRI Scan visit through 1 month after MRI scan visit

    Percentage of patients who do not have MRI-related complications from the MRI scan visit to the 1 month post MRI scan visit

  6. Change in Atrial Capture Threshold From Pre to Post MRI Scan

    Time frame: MRI Scan visit to 1 month after MRI scan visit

    Percentage of patients with an increase in RA capture thresholds of <= 0.5 V, at a pulse width of 0.5 ms .

  7. Change in Ventricular Capture Threshold Pre to Post MRI Scan

    Time frame: MRI Scan visit to 1 month after MRI scan visit

    Percentage of patients with an increase in RV capture thresholds of <=0.5V, at a pulse width of 0.5 ms.

  8. Change in Atrial Sense Amplitude

    Time frame: MRI Scan visit to 1 month after MRI scan visit

    Percentage of patients with a reduction in RA sense amplitude <=50 % and sense amplitude >=1.5 mV.

  9. Change in Ventricular Sense Amplitude

    Time frame: MRI Scan visit to 1 month after the MRI Scan visit

    Percentage of patients with an reduction in RV sense amplitude <=50% and sense amplitude >=5 mV.

Secondary outcomes

  1. Freedom From System-related Complications

    Time frame: Implant through 12 months

    Percentage of patients who do not have system-related complications from implant through the 12 month study visit

  2. Atrial Capture Threshold at the MRI Visit

    Time frame: MRI Scan visit (approx 3 months post implant)

    Percentage of patients with RA capture threshold ≤2.0 volts (V) at the MRI visit

  3. Ventricular Capture Threshold at the MRI Visit

    Time frame: MRI Scan visit (approx 3 months post implant)

    Percentage of patients with RV capture threshold ≤2.0 V at the MRI visit

Sponsors and collaborators

Lead sponsor

Abbott Medical Devices

Industry

Registry information

Official study title

Accent Magnetic Resonance Imaging Pacemaker and Tendril Magnetic Resonance Imaging™ Lead Investigational Device Exemption Study

Important dates

Study start
2012
Primary completion
2018
Study completion
2018
First posted
Apr 12, 2012
Registry last updated
Nov 10, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.